Letter from the Editor

Dear Colleagues,

We thank you for your interest in this edition of Medicom’s Conference Reports focused on the 2021 American College of Cardiology (ACC) Annual Scientific Sessions. This year’s ACC meeting was rich with late-breaking presentations and cutting-edge science.

Topics ranging from heart failure, vascular medicine, electrophysiology, and COVID 19 are covered. Late-breaking trials including PARADISE MI, DARE, REHAB-HF presented their primary results and are described in the following concise summaries. Important clinical trial updates including the total burden of vascular events in VOYAGER PAD and sex and outcomes from TWILIGHT are also presented.

We hope you find the following pages to be informative, concise, and balanced as our editorial team constantly strives to produce the highest quality summaries. Most of all, we hope you and your families are safe and healthy, we thank you for your contributions through this difficult time, and we hope to see you in person at upcoming events.

 

Sincerely,

Marc Bonaca



 

Biography

Marc P. Bonaca, MD, MPH, is a Cardiologist and Vascular Medicine Specialist who serves as the Executive Director of CPC Clinical Research and CPC Community Health at the University of Colorado Anschutz Medical Campus. He is the Director of Vascular Research and an Associate Professor of Medicine at the University of Colorado School of Medicine and the inaugural holder of the William R. Hiatt Endowed Chair in Cardiovascular Research.

Dr Bonaca earned his medical degree from the University of Connecticut School of Medicine and his Masters in Public Health at Harvard University. He served as a Medical House Officer at Brigham and Women’s Hospital and Harvard Medical School. After completion of his training he joined the faculty of the Cardiovascular Division and Vascular Medicine section of Brigham and Women’s Hospital and Harvard Medical School and became an Investigator at the TIMI Study Group.

Dr Bonaca’s research focus is on ischemic risk in patients with atherosclerotic vascular disease, risk prediction, and risk modification through the use of pharmacologic and biologic therapies. His key areas of interest include patients with peripheral artery disease, polyvascular disease and diabetes with a focus on the breadth of risk including ischemic limb outcomes, microvascular complications and major adverse cardiovascular events.

Conflict of Interest Statement:

Grant support to BWH from AstraZeneca, MedImmune, Merck, PfizerGrant support to CPC from Amgen, AstraZeneca, Bayer, Janssen, NovoNordisk, Sanofi

 



Posted on 9 July, 20219 July, 2021